P
AZN icon

&Partners’s AstraZeneca AZN Stock Holding History

&Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.9M Buy
70,365
+2,803
+4% +$540K 0.07% 264
2025
Q4 		$12.4M Buy
67,562
+10,932
+19% +$1.92M 0.07% 265
2025
Q3 		$8.69M Buy
56,630
+3,977
+8% +$602K 0.06% 295
2025
Q2 		$7.36M Buy
52,653
+9,411
+22% +$1.32M 0.06% 290
2025
Q1 		$6.42M Sell
43,242
-2,748
-6% -$398K 0.07% 250
2024
Q4 		$6.08M Buy
45,990
+18,790
+69% +$2.63M 0.07% 248
2024
Q3 		$4.24M Buy
27,200
+19,389
+248% +$3.13M 0.08% 229
2024
Q2 		$1.22M Buy
+7,811
New +$1.18M 0.05% 298

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

&Partners's AZN Position: Q1 2026 in Review

&Partners increased its AstraZeneca (AZN) stake by 4.1% in Q1 2026, buying an estimated $540K and bringing the position to 70,365 shares worth $13.9M. The position accounts for 0.07% of the portfolio, ranked #264.

&Partners first reported a position in AZN in Q2 2024 and has held it in 8 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • &Partners held 70,365 shares of AstraZeneca worth $13.9M as of Q1 2026.
  • &Partners bought 2,803 AstraZeneca shares in Q1 2026, an estimated $540K.
  • AstraZeneca made up 0.07% of &Partners's portfolio in Q1 2026, its #264 holding.
  • &Partners first reported a position in AstraZeneca in Q2 2024 and has held it in 8 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.